Navigation Links
Aratana Therapeutics Announces $20 Million Financing
Date:1/7/2011

KANSAS CITY, Kan., Jan. 7, 2011 /PRNewswire/ -- Aratana Therapeutics, a newly-formed company focused on the development of innovative therapies for the animal health industry, today announced that it has closed a $20 million Series A financing led by MPM Capital and Avalon Ventures.

"At Aratana, we will be focused on taking advancements from the human biopharmaceutical industry and applying them in new ways to treat and care for animals," said Dr. David Rosen, President and Founder of Aratana Therapeutics. "The addition of Dr. Linda Rhodes as CEO and the closing of the $20 million in financing are two major milestones that set Aratana up for future success moving forward."  

Dr. Linda Rhodes, a recognized leader in the fields of human and animal drug discovery and development, will join Aratana in February 2011 as Chief Executive Officer. Previously, Dr. Rhodes was founder and vice-president of clinical development at AlcheraBio, an entrepreneurial contract research organization devoted to helping major animal health companies develop new drugs.

"My entire career has been devoted to developing therapies for animals, and I am looking forward to continuing that work in this exciting, venture-capital model at Aratana," said Dr. Rhodes.

"Drs. Rhodes and Rosen are the perfect duo to execute the vision we have for Aratana," said Dr. Steven St. Peter, Managing Director at MPM Capital.  "Both are veterinarians, one with extensive drug development expertise and the other with extensive business development expertise."

Aratana's board of directors will include Dr. Rhodes; Dr. Steven St. Peter, Managing Director at MPM Capital; Jay Lichter, Managing Director at Avalon Ventures; and Ron Meeusen, Founder of Cultivian Ventures. Other investors in the round of financing include the Kansas Bioscience Authority.


'/>"/>
SOURCE Aratana Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
2. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
3. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
4. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
5. Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
6. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
7. CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
8. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
9. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
10. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
11. Arno Therapeutics Announces Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Houston Methodist Willowbrook ... Cy-Fair Sports Association to serve as their official ... Houston Methodist Willowbrook will provide sponsorship support, athletic ... with association coaches, volunteers, athletes and families. ... Cy-Fair Sports Association and to bring Houston Methodist ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only ... Center and will showcase its product’s latest features from June 26 to June ... scientific poster on Disrupting Clinical Trials in The Cloud during the conference. ...
Breaking Biology Technology:
(Date:5/16/2016)... 16, 2016   EyeLock LLC , a market ... opening of an IoT Center of Excellence in ... the development of embedded iris biometric applications. ... convenience and security with unmatched biometric accuracy, making it ... from DNA. EyeLock,s platform uses video technology to deliver ...
(Date:5/9/2016)... UAE, May 9, 2016 Elevay ... comes to expanding freedom for high net worth professionals ... in today,s globally connected world, there is still no ... could ever duplicate sealing your deal with a firm ... passports by taking advantage of citizenship via investment programs ...
(Date:4/28/2016)... FRANCISCO and BANGALORE, India , ... of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... provider, today announced a global partnership that will ... way to use mobile banking and payment services. ... is a key innovation area for financial services, but it ...
Breaking Biology News(10 mins):